Evofem Biosciences Balance Sheet Health
Financial Health criteria checks 0/6
Evofem Biosciences has a total shareholder equity of $-66.1M and total debt of $44.7M, which brings its debt-to-equity ratio to -67.5%. Its total assets and total liabilities are $23.9M and $90.1M respectively.
Key information
-67.5%
Debt to equity ratio
US$44.65m
Debt
| Interest coverage ratio | n/a |
| Cash | US$202.00k |
| Equity | -US$66.13m |
| Total liabilities | US$90.07m |
| Total assets | US$23.94m |
Recent financial health updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Financial Position Analysis
Short Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVFM has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVFM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EVFM has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EVFM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 15:15 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evofem Biosciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Tanner | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |